Tech Company Financing Transactions

Omeros Funding Round

Stanley Medical Research Group participated in a $9 million funding round for Omeros. This venture round was announced on 1/11/2007.

Transaction Overview

Company Name
Announced On
1/11/2007
Transaction Type
Venture Equity
Amount
$9,000,000
Round
Undisclosed
Proceeds Purpose
The money will be used to continue development on a drug treatment for schizophrenia.

Company Information

Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
201 Elliott Ave. West The Omeros Building
Seattle, WA 98119
USA
Email Address
Overview
Omeros recognized that a combination of agents acting on multiple molecular targets may be required for optimal therapeutic effect. Omeros' product candidates are designed to modulate the molecular mechanisms of pathologic conditions rather than just treating their symptoms.
Profile
Omeros LinkedIn Company Profile
Social Media
Omeros Company Twitter Account
Company News
Omeros News
Facebook
Omeros on Facebook
YouTube
Omeros on YouTube

Management Team

Title
Name
Email & Social
Chief Executive Officer
Gregory Demopulos
  Gregory Demopulos LinkedIn Profile  Gregory Demopulos Twitter Account  Gregory Demopulos News  Gregory Demopulos on Facebook
Chief Medical Officer
Steven Whitaker
  Steven Whitaker LinkedIn Profile  Steven Whitaker Twitter Account  Steven Whitaker News  Steven Whitaker on Facebook
Chief Scientific Officer
George Gaitanaris
  George Gaitanaris LinkedIn Profile  George Gaitanaris Twitter Account  George Gaitanaris News  George Gaitanaris on Facebook
VP - Bus. Development
Timothy Duffy
  Timothy Duffy LinkedIn Profile  Timothy Duffy Twitter Account  Timothy Duffy News  Timothy Duffy on Facebook
VP - Finance
Michael Jacobsen
  Michael Jacobsen LinkedIn Profile  Michael Jacobsen Twitter Account  Michael Jacobsen News  Michael Jacobsen on Facebook
VP - Regulatory Affairs
Catherine Melfi
  Catherine Melfi LinkedIn Profile  Catherine Melfi Twitter Account  Catherine Melfi News  Catherine Melfi on Facebook


 

 

Browse more venture capital transactions:

Prev: 1/10/2007: AdmitOne Security venture capital transaction
Next: 1/11/2007: InteKrin Therapeutics venture capital transaction

 

Share this article

 


Where The Data Comes From

We do our best to report on every notable VC transaction. All VC database entries reported here are sourced from a variety of public sources. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.

 


Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary